143 related articles for article (PubMed ID: 31444112)
1. Clinical significance of post-treatment viral load of cytomegalovirus in patients with hematologic malignancies.
Lu W; Chen HP; Chan YJ; Wang FD
J Microbiol Immunol Infect; 2021 Apr; 54(2):245-252. PubMed ID: 31444112
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
3. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of human cytomegalovirus viruria and the effect of antiviral therapy in hematopoietic stem cell transplant recipients.
Wei-Lu ; Chen SJ; Huang SF; Chan YJ; Wang FD; Chen HP
J Microbiol Immunol Infect; 2019 Jun; 52(3):402-408. PubMed ID: 29126804
[TBL] [Abstract][Full Text] [Related]
5. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
[TBL] [Abstract][Full Text] [Related]
6. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
Tan SK; Waggoner JJ; Pinsky BA
J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
[TBL] [Abstract][Full Text] [Related]
8. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus viremia in lung transplantation during and after prophylaxis.
Chang A; Musk M; Lavender M; Wrobel J; Yaw MC; Lawrence S; Chirayath S; Boan P
Transpl Infect Dis; 2019 Jun; 21(3):e13069. PubMed ID: 30884067
[TBL] [Abstract][Full Text] [Related]
10. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
[TBL] [Abstract][Full Text] [Related]
12. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
13. Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status.
Damlaj M; Khalid F; Alahmari B; Alaskar A; Ghazi S; Johani S; AlSaedy A; Bosaeed M; Alhejazi A; Al-Zahrani M
Curr Res Transl Med; 2020 Aug; 68(3):131-137. PubMed ID: 32620466
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.
Jang JE; Hyun SY; Kim YD; Yoon SH; Hwang DY; Kim SJ; Kim Y; Kim JS; Cheong JW; Min YH
Biol Blood Marrow Transplant; 2012 Jun; 18(6):881-6. PubMed ID: 22062802
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
16. [Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation].
Wang Y; Huang XJ; Xu LP; Liu DH; Chen YH; Han W; Wang J; Liu KY
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(46):3265-7. PubMed ID: 19159551
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation.
Jeon S; Lee WK; Lee Y; Lee DG; Lee JW
Ophthalmology; 2012 Sep; 119(9):1892-8. PubMed ID: 22657564
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Infection Downregulates Vitamin D Receptor in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Robak O; Kastner MT; Stecher C; Schneider M; Andreas M; Greinix H; Kallay E; Honsig C; Steininger C
Transplantation; 2021 Jul; 105(7):1595-1602. PubMed ID: 32890131
[TBL] [Abstract][Full Text] [Related]
19. Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high-risk cytomegalovirus serostatus kidney transplant recipients.
Magua W; Johnson AC; Karadkhele GM; Badell IR; Vasanth P; Mehta AK; Easley KA; Newell KA; Rickert JB; Larsen CP
Transpl Infect Dis; 2022 Dec; 24(6):e13983. PubMed ID: 36321801
[TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
